Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients
Open Access
- 26 August 2020
- journal article
- editorial
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-4
Abstract
There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.Keywords
This publication has 15 references indexed in Scilit:
- Pathogenesis and transmission of SARS-CoV-2 in golden hamstersNature, 2020
- Respiratory disease in rhesus macaques inoculated with SARS-CoV-2Nature, 2020
- Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South KoreamedRxiv, 2020
- Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemicsbioRxiv, 2020
- Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivobioRxiv, 2020
- Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and TransmissibilityClinical Infectious Diseases, 2020
- Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epitheliaScientific Reports, 2019
- Matched-Comparative Modeling of Normal and Diseased Human Airway Responses Using a Microengineered Breathing Lung ChipCell Systems, 2016
- Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitroNature Methods, 2015
- The Genome Landscape of the African Green Monkey Kidney-Derived Vero Cell LineDNA Research, 2014